

# Andexxa

(coagulation factor Xa [recombinant],  
inactivated-zhzo)



**NEW PRODUCT SLIDESHOW**

**MPR**

# Introduction

- **Brand name:** Andexxa
- **Generic name:** Coagulation factor Xa (recombinant), inactivated-zhzo
- **Pharmacological class:** Factor Xa (recombinant)
- **Strength and Formulation:** 100mg; per vial; lyophilized powder for IV inj after reconstitution; preservative-free
- **Manufacturer:** Portola
- **How supplied:** Single-use vials—4
- **Legal Classification:** Rx

# Indication

- Reversal of anticoagulation with **rivaroxaban** or **apixaban** due to life-threatening or uncontrolled bleeding

# Limitations of Use

- Not effective for, and not indicated for, the treatment of bleeding related to **any FXa inhibitors** other than apixaban and rivaroxaban

# Dosage & Administration

- For IV use only
- **Low-dose regimen:** initially 400mg (target rate: 30mg/min) as IV bolus, followed by 4mg/min IV infusion for up to 120mins

# Dosage & Administration

- **High-dose regimen:** initially 800mg (target rate: 30mg/min) as IV bolus, followed by 8mg/min IV infusion for up to 120mins
- If last rivaroxaban dose  $\leq 10\text{mg}$  or apixaban dose  $\leq 5\text{mg}$  given  $< 8\text{hrs}$  (or unknown): use **low-dose** regimen

# Dosage & Administration

- If last rivaroxaban dose  $>10\text{mg}$ /unknown or apixaban dose  $>5\text{mg}$ /unknown given  $<8\text{hrs}$  (or unknown): use **high-dose** regimen
- If rivaroxaban or apixaban dose given  $\geq 8\text{hrs}$ : use **high-dose** regimen

# Considerations for Special Populations

- **Pregnancy:** No adequate data to inform associated risks
- **Nursing mothers:** Consider benefits with mother's need and potential adverse effects on infant
- **Labor & delivery:** Not evaluated
- **Pediatric:** Not studied
- **Elderly:** No overall differences observed



# Warnings/Precautions

- Risk of **serious events** (eg, thromboembolism, ischemia, cardiac arrest, sudden deaths); monitor for signs/symptoms; resume anticoagulant therapy as soon as medically appropriate after Andexxa
- **Re-elevation or incomplete reversal** of anti-FXa activity can occur

# Adverse Reactions

- Urinary tract infections
- Pneumonia
- Infusion-related reactions

# Mechanism of Action

- **Coagulation factor Xa (recombinant), inactivated-zhzo** exerts its procoagulant effect by binding and sequestering the FXa inhibitors, rivaroxaban and apixaban
- It also inhibits the activity of Tissue Factor Pathway Inhibitor (TFPI), which can increase tissue factor-initiated thrombin generation

# Clinical Studies

- Andexxa was evaluated in 2 prospective, randomized, placebo-controlled studies that examined the **percent change in anti-FXa activity**, from baseline to nadir, for the low-dose and high-dose regimens
  - Nadir is defined as the smallest value measured within 5 minutes after end of continuous infusion

# Clinical Studies

- In **Study 1** (N=32), healthy patients received Andexxa or placebo 3 hours after the last **apixaban** dose
- There was a statistically significant percent change from baseline in anti-FXa activity with Andexxa vs placebo (mean change of **-92.3%** vs **-32.7%**; difference **-59.5%** [95% CI, **-64.1, -55.2**];  $P < .0001$ )

# Clinical Studies

- In **Study 2** (N=39), healthy patients received Andexxa or placebo 4 hours after the last **rivaroxaban** dose
- There was a statistically significant percent change from baseline in anti-FXa activity with Andexxa vs placebo (mean change of **-96.7%** vs **-44.6%**; difference **-51.9%** [95% CI, **-58.0, -47.0**];  $P < .0001$ )

# Clinical Studies

- **ANNEXA-4** is an ongoing multinational, prospective, single-arm, open-label study of Andexxa administered to patients taking FXa inhibitors who presented with acute major bleeding
  - Interim data included 185 patients of which 129 were considered efficacy-evaluable

# Clinical Studies

- For anti-FXa activity, the median decrease from baseline to nadir was **-93%** for apixaban and **-90%** for rivaroxaban
- For more clinical trial data, see full labeling



# New Product Monograph

- For more information view the product monograph available at:

<http://www.empr.com/andexxa/drug/34844/>